» Articles » PMID: 20686618

A Simple and Sensitive Method for Measuring Tumor-specific T Cell Cytotoxicity

Overview
Journal PLoS One
Date 2010 Aug 6
PMID 20686618
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

A simple and sensitive method to quantitatively measure the cytolytic effect of tumor-specific T killer cells is highly desirable for basic and clinical studies. Chromium (51Cr) release assay has been the "gold standard" for quantifying cytolytic activities of cytotoxic T lymphocytes (CTLs) against target cells and this method is still being used in many laboratories. However, a major drawback of this method is the use of radioactive materials, which is inconvenient to handle because of environmental safety concerns and expensive due to the short half-life of the isotope. Consequently, several nonradioactive methods have been reported recently. Here we report a new method that we recently developed for quantifying antigen-specific cytolytic activity of CTLs. This method fully exploits the high sensitivity and the relative simplicity of luciferase quantitative assay. We initially expected the released luciferase in the supernatant to be the adequate source for monitoring cell death. However, to our total surprise, incubation of these killer T cells with the tumor cell targets did not result in significant release of luciferase in the culture medium. Instead, we found that the remaining luciferase inside the cells could accurately reflect the overall cell viability.

Citing Articles

Probiotic neoantigen delivery vectors for precision cancer immunotherapy.

Redenti A, Im J, Redenti B, Li F, Rouanne M, Sheng Z Nature. 2024; 635(8038):453-461.

PMID: 39415001 PMC: 11560847. DOI: 10.1038/s41586-024-08033-4.


A dual-luciferase bioluminescence system for the assessment of cellular therapies.

Torres Chavez A, McKenna M, Balasubramanian K, Riffle L, Patel N, Kalen J Mol Ther Oncol. 2024; 32(1):200763.

PMID: 38596291 PMC: 10869576. DOI: 10.1016/j.omton.2024.200763.


A Promising New Model: Establishment of Patient-Derived Organoid Models Covering HPV-Related Cervical Pre-Cancerous Lesions and Their Cancers.

Hu B, Wang R, Wu D, Long R, Fan J, Hu Z Adv Sci (Weinh). 2024; 11(12):e2302340.

PMID: 38229169 PMC: 10966527. DOI: 10.1002/advs.202302340.


Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.

Meng F, Zhang S, Xie J, Zhou Y, Wu Q, Lu B J Hematol Oncol. 2023; 16(1):62.

PMID: 37316891 PMC: 10265820. DOI: 10.1186/s13045-023-01455-z.


Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.

Watanabe K, Gomez A, Kuramitsu S, Siurala M, Da T, Agarwal S Blood Adv. 2023; 7(14):3416-3430.

PMID: 37058474 PMC: 10345856. DOI: 10.1182/bloodadvances.2022008327.


References
1.
Nelson D, Kurman C, Serbousek D . 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC). Curr Protoc Immunol. 2008; Chapter 7:Unit 7.27. DOI: 10.1002/0471142735.im0727s08. View

2.
Cohen C, Li Y, El-Gamil M, Robbins P, Rosenberg S, Morgan R . Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007; 67(8):3898-903. PMC: 2147081. DOI: 10.1158/0008-5472.CAN-06-3986. View

3.
Chen K, Chen L, Zhao P, Marrero L, Keoshkerian E, Ramsay A . FL-CTL assay: fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells. J Immunol Methods. 2005; 300(1-2):100-14. DOI: 10.1016/j.jim.2005.02.010. View

4.
Andre N, Barbosa D, Munhoz E, Estevao D, Cecchini R, Watanabe M . Measurement of cytotoxic activity in experimental cancer. J Clin Lab Anal. 2004; 18(1):27-30. PMC: 6807731. DOI: 10.1002/jcla.20006. View

5.
Harty J, Tvinnereim A, White D . CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 2000; 18:275-308. DOI: 10.1146/annurev.immunol.18.1.275. View